BioCentury | Nov 20, 2006
Company News

Inovio Biomedical, VGX deal

...VGX (formerly Viral Genomix Inc.) received a worldwide non-exclusive license to INO's DNA delivery technology for intratumoral electroporation...
BioCentury | Nov 6, 2006
Regulation

HCV antivirals

...Nitrothiazolyl-salicylamide compound Ph II (C ) Schering-Plough SCH 503034 HCV NS3 protease inhibitor Ph II Viral Genomix...
Items per page:
1 - 2 of 2
BioCentury | Nov 20, 2006
Company News

Inovio Biomedical, VGX deal

...VGX (formerly Viral Genomix Inc.) received a worldwide non-exclusive license to INO's DNA delivery technology for intratumoral electroporation...
BioCentury | Nov 6, 2006
Regulation

HCV antivirals

...Nitrothiazolyl-salicylamide compound Ph II (C ) Schering-Plough SCH 503034 HCV NS3 protease inhibitor Ph II Viral Genomix...
Items per page:
1 - 2 of 2